METFORMIN IN OBESE ADOLESCENTS

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Currently, there is an epidemic of obesity among American youth. As a result, health problems related to obesity, such as high blood pressure, elevated cholesterol levels and diabetes, have increased among this population as well. A number of adolescents have been and are currently being treated for obesity with metformin, despite a lack of scientific data supporting its use. This trial will test the hypothesis that among obese adolescents, treatment with extended-release Metformin (Glucophage XR), coupled with a lifestyle intervention, will result in decreased obesity as compared to subjects who receive treatment with placebo and the same lifestyle intervention. Approximately 135 potential subjects will be screened in order to randomize 76 obese adolescents between the ages of 13-18 yrs old. Obesity will be assessed by measuring each subject's body mass index (BMI). BMI provides a guideline based on weight and height to determine whether an individual is at an appropriate weight.